查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球胰岛素输液帮浦市场 -2023-2030
市场调查报告书
商品编码
1374789

全球胰岛素输液帮浦市场 -2023-2030

Global Insulin Infusion Pumps Market -2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

胰岛素输注帮浦是小型电脑化设备。胰岛素帮浦可以帮助糖尿病患者方便地管理血糖。这些小型设备在特定时间内提供一定剂量的胰岛素。许多人发现胰岛素帮浦比胰岛素笔注射等其他设备更灵活。胰岛素帮浦不必是永久性的，可以随时切换到另一种胰岛素管理方法。

众所周知，胰岛素帮浦可以提供自由和灵活性的生活方式。所有第 1 型糖尿病患者和一些第 2 型糖尿病患者在余生都需要某种类型的胰岛素注射选择，这些胰岛素帮浦可以让糖尿病治疗变得更加容易。剂量透过称为导管的柔性塑胶管输送。在小针的帮助下，将导管穿过皮肤插入脂肪组织并用胶带固定到位。管/针组合称为输液器。

市场动态：驱动因素

越来越多采用先进的胰岛素输注泵

先进胰岛素输注帮浦的日益普及预计将在预测期内推动市场发展。胰岛素输注帮浦的进步有助于更好地治疗糖尿病，进而改善患者的治疗效果。例如，2022年3月8日，美敦力公司的全资子公司India Medtronic Private Limited在印度推出了MiniMed 780G系统。

MiniMed 780G系统是下一代闭环胰岛素帮浦系统，用于治疗7至80岁族群的第一型糖尿病。该系统利用该公司最先进的 SmartGuard 技术，每五分钟自动输送基础胰岛素和校正推注，帮助糖尿病患者更轻鬆地避免情绪高涨和低谷。

此外，胰岛素输注帮浦比其他设备具有更大的优势，这些帮浦的进步有助于控制和管理胰岛素输注。先进的输液帮浦提供更精确和持续的胰岛素输送，可以显着改善血糖控制。这可以为糖尿病患者带来更好的长期健康结果并减少併发症。

例如，2023年2月14日，EOFlow Co.在阿联酋推出了其无管、可穿戴、一次性胰岛素帮浦「EOPatch」。在阿联酋，可以使用全新的 Narsha 应用程式直接透过 Android 和 iOS 智慧型手机透过 EOPatch 控制和管理胰岛素输注。

此外，监管部门的批准增加了患者对新型先进设备开发的信任。例如，2022 年 2 月 16 日，领先的胰岛素输送和糖尿病技术公司 Tandem Diabetes Care, Inc. 发布了美国食品和药物管理局 (FDA) 批准的 t : slim X2 胰岛素泵的推注胰岛素剂量，使用t ：连接行动应用程式。这是首款获得 FDA 批准的智慧型手机应用程序，能够在 iOS 和 Android 作业系统上启动胰岛素传输。

此外，糖尿病盛行率的增加、FDA 批准的增加、临床试验的增加、新型设备开发的意识增强和技术进步预计将在预测期内推动市场发展。

限制

与设备相关的併发症、胰岛素输注帮浦的高成本、与设备相关的技术问题以及替代治疗方案的存在等因素预计将阻碍市场。

目录

第 1 章：方法与范围

  • 研究方法论
  • 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

  • 按组件分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 4 章：动力学

  • 影响因素
    • 司机
      • 越来越多采用先进的胰岛素输注泵
    • 限制
      • 与设备相关的併发症
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 监管分析
  • 管道分析
  • 未满足的需求
  • 专利分析
  • DMI 意见

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆发前的情景
    • 新冠疫情期间的情景
    • 新冠疫情后的情景
  • COVID-19 期间的定价动态
  • 供需谱
  • 疫情期间政府与市场相关的倡议
  • 製造商策略倡议
  • 结论

第 7 章：按组件

  • 胰岛素帮浦
  • 点滴器
  • 水库

第 8 章：按应用

  • I 型糖尿病
  • II型糖尿病

第 9 章：最终用户

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • Medtronic plc
    • 公司简介
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Insulet Corporation
  • Tandem Diabetes Care, Inc.
  • Ascensia Diabetes Care Holdings AG
  • Ypsomed AG
  • F. Hoffmann-La Roche Ltd.
  • Shinmyung Mediyes CO., LTD.
  • Abbott Laboratories
  • SOOIL Developments Co., Ltd
  • Smiths Group plc

第 13 章：附录

简介目录
Product Code: MD7199

Overview

Insulin infusion pumps are small and computerized devices. Insulin pumps can help diabetes patients conveniently manage their blood sugar. These small devices deliver doses of insulin at specific times. Many people find that insulin pumps are a more flexible option than other devices like insulin pen injections. Insulin pumps don't have to be permanent and can switch to another insulin management method at any time.

Insulin pumps are known to offer lifestyle freedom and flexibility. All people with Type 1 diabetes and some people with Type 2 diabetes will need some type of insulin injection option for the rest of their lives, these insulin pumps can make diabetes treatment more easier. Doses are delivered through a flexible plastic tube known as a catheter. With the aid of a small needle, the catheter is inserted through the skin into the fatty tissue and is taped in place. The tube/needle combination is called an infusion set.

Market Dynamics: Drivers

Increasing adoption of advanced insulin infusion pumps

The increasing adoption of advanced insulin infusion pumps is expected to drive the market over the forecast period. The advancements in insulin infusion pumps helps in the better treatment of diabetes, resulting in better patient outcomes. For instance, on March 08, 2022, India Medtronic Private Limited, a wholly owned subsidiary of Medtronic plc launched the MiniMed 780G system in India.

The MiniMed 780G system is a next-generation closed-loop insulin pump system for the treatment of type 1 diabetes in people aged 7 to 80 years. Leveraging the company's most advanced SmartGuard technology, the system automates the delivery of both basal insulin and correction boluses every five minutes to help people with diabetes avoid highs and lows with greater ease.

Moreover, insulin infusion pumps have greater advantages than other devices, the advancements in these pumps helps to control and manage the insulin infusions. Advanced infusion pumps offer more precise and continuous insulin delivery, which can significantly improve blood glucose control. This can lead to better long-term health outcomes and reduced complications for individuals with diabetes.

For instance, on february 14, 2023, EOFlow Co. launched its tubeless, wearable, and disposable insulin pump "EOPatch" in the UAE. It becomes possible in the UAE to control and manage insulin infusions with EOPatch directly from Android and iOS smartphones using the brand-new Narsha app.

In addition, the regulatory approvals increase the trust in patients about the development of novel advanced devices. For instance, on February 16, 2022, Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, released the U.S. Food and Drug Administration (FDA) clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. This represents the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems.

Further, the increasing prevalence of diabetes, rising FDA approvals, increasing clinical trials, increasing awareness and technological advancements in the development of novel devices are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the devices, the high cost of the insulin infusion pumps, technical issues associated with the devices and presence of alternative treatment options are expected to hamper the market.

Segment Analysis

The global insulin infusion pumps market is segmented based on component, application, end-user and region.

The insulin pumps segment accounted for approximately 45.3% of the insulin infusion pumps market share

The insulin pumps segment is expected to hold the largest market share over the forecast period. The increasing prevalence of diabetes is expected to increase the demand for the insulin pumps. For instance, according to the Centers for Disease Control and Prevention, 2022, 37.3 million people have diabetes.

Ongoing advancements in insulin pump technology, such as integration with continuous glucose monitoring (CGM) systems and improved user interfaces, may attract more users. Insulin pumps offer flexibility in insulin dosing, allowing users to customize their treatment plans. Their convenience, including reduced injection frequency, can make them an attractive option.

For instance, on April 25, 2023, Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod brand of products, released the FDA clearance of its latest innovation, Omnipod GO, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin.

Geographical Analysis

North America accounted for approximately 39.2% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and technological advancements. North America especially the United States is known for its strong presence of major players such as pharmaceutical companies and medical device companies. The presence of major players actively performing in clinical trials, leads to the launch of novel and advanced devices in the region.

For instance, on November 15, 2022, Medtronic launched a new infusion set with a wear time of up to seven days for insulin pumps in the US. Developed in collaboration with Convatec Infusion Care, the new Medtronic Extended Infusion Set is claimed to be the first and only infusion set that is designed for double the wear time. The new infusion set leverages advanced materials to help minimize insulin preservative loss, maintain insulin flow and stability, and double the infusion set wear time.

Furthermore, the region is also known for its innovation and investment in research and development in the insulin infusion pumps. Technological advancements in North America especially in United States can lead to the introduction of cutting-edge products and solutions that attract a more users.

In addition, on July 07, 2020, Medtronic plc, the global leader in medical technology, introduced the MiniMed Mio Advance infusion set to all Medtronic insulin pump customers in the United States. The MiniMed Mio Advance infusion set is the newest addition to the MiniMed portfolio of infusion sets and gives people using insulin pumps an optimal user experience with fewer steps.

Competitive Landscape

The major global players in the insulin infusion pumps market include: Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Ascensia Diabetes Care Holdings AG, Ypsomed AG, F. Hoffmann-La Roche Ltd., Shinmyung Mediyes CO., LTD., Abbott Laboratories, SOOIL Developments Co., Ltd and Smiths Group plc, among others.

Key Developments

  • On June 21, 2023, Insulet commercially launched its Omnipod 5 automated insulin delivery system in the United Kingdom. Acton, Massachusetts-based Insulet launched Omnipod 5 insulin pumps for individuals aged two years and older with type 1 diabetes.
  • On April 21, 2023, Medtronic plc, the global leader in medical technology, cleared the U.S. Food and Drug Administration (FDA) approval of its MiniMed 780G system with the Guardian 4 sensor requiring no fingersticks while in SmartGuard technology. This milestone marks the approval of the only system with meal detection technology that provides automatic adjustments and corrections to sugar levels every 5 minutes.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global insulin infusion pumps market. Many people with diabetes reduced their visits during the pandemic to minimize the risk of exposure to the virus. As a result, there was a decline in new pump prescriptions and fittings, impacting market growth. Healthcare providers increasingly turned to telehealth and remote monitoring solutions to provide care to individuals with diabetes. The pandemic also disrupted the supply chain of these devices globally.

Why Purchase the Report?

  • To visualize the global insulin infusion pumps market segmentation based on component, application end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of insulin infusion pumps market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as excel consisting of key products of all the major players.

The global insulin infusion pumps market report would provide approximately 61 tables, 57 figures, and 188 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Component
  • 3.2. Snippet by Application
  • 3.3. Snippet by End-User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Adoption of Advanced Insulin Infusion Pumps
    • 4.1.2. Restraints
      • 4.1.2.1. Complications Associated with the Devices
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Unmet Needs
  • 5.7. Patent Analysis
  • 5.8. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Component

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 7.1.2. Market Attractiveness Index, By Component
  • 7.2. Insulin Pumps*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Infusion Sets
  • 7.4. Reservoirs

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Type I Diabetes*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Type II Diabetes

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Specialty Clinics
  • 9.4. Home Care Settings
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Component
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Medtronic plc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Insulet Corporation
  • 12.3. Tandem Diabetes Care, Inc.
  • 12.4. Ascensia Diabetes Care Holdings AG
  • 12.5. Ypsomed AG
  • 12.6. F. Hoffmann-La Roche Ltd.
  • 12.7. Shinmyung Mediyes CO., LTD.
  • 12.8. Abbott Laboratories
  • 12.9. SOOIL Developments Co., Ltd
  • 12.10. Smiths Group plc

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us